October 23, 2013
A rout has turn to stragglers retreating
October 21, 2013
StemCells (STEM) Results Batten Disease study - SELL
October 14, 2013
The rules of Washington’s “Thunderdome” are simple: "Two men enter, one man leaves."
October 11, 2013
Scanning the skies for OSIR’s and MBLTY’s ADR share price as fiscal fog continues
October 10, 2013
The musical chairs of share pricing
October 10, 2013
Cytori (CYTX) Patent in Australia
October 9, 2013
A Congressional duel begets a risky trajectory for RegMed
October 8, 2013
Trading weakness and volume malaise
October 4, 2013
Stem Cells engineered to become Targeted Drug Factories
September 11, 2013
A moment of silence
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.